Moderna Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for the treatment of cystic fibrosis (CF).
Strand Therapeutics is genetically programming RNA not just to deliver a gene of interest, but to control the location, timing and intensity of therapeutic protein expression using mRNA-encoded logic circuits.
Tianjin, China’s CanSino Biologics entered into a co-development agreement with Vancouver, British Columbia’s Precision NanoSystems for an mRNA lipid nanoparticle vaccine against COVID-19.
The software of life is how Moderna Inc. CEO Stephane Bancel describes messenger RNA (mRNA), which is at the core of the company’s drug development process.
Cambridge, Mass.-based Dicerna Pharmaceuticals signed a research collaboration and licensing deal with Switzerland’s Roche for chronic hepatitis B virus therapies that could hit $1.67 billion.
Cambridge, Mass.-based bluebird bio and Bagsvaerd, Denmark-based Novo Nordisk agreed to develop next-generation genome editing therapies for genetic diseases, including hemophilia.
Anima Biotech technology uses state-of-the-art molecular biology that can illuminate the protein synthesis process and identify small molecules that regulate mRNA translation.
Researchers may have found a solution to treating a bone marrow cancer proven to be resistant to several standard therapies.
Tubingen, Germany-based CureVac entered a collaboration research agreement with Yale University to focus on lung therapies.
San Diego-based Arcturus Therapeutics Ltd. announced that the company was reassuming 100 percent of its global rights from Germany-based CureVac AG for ARCT-810, a messenger RNA (mRNA) drug to treat OTC deficiency.